首页> 外文会议>Nestlé Nutrition Workshop >Probiotic Supplementation for Preterm Neonates - What Lies Ahead?
【24h】

Probiotic Supplementation for Preterm Neonates - What Lies Ahead?

机译:益生菌补充剂的早产儿 - 前方有什么?

获取原文

摘要

Systematic reviews of randomized controlled trials indicate that probiotic supplementation significantly reduces the riskofnecrotizingenterocolitis (NEC) without adverse effects in preterm very-low-birthweight neonates. A change in practice in favor of probiotic supplementation is justified considering the health burden of NEC in this population. The reduction in the risk of NEC seems to occur even when the baseline incidence of the illness is as low as 5%. Facilitation of feed tolerance is a significant benefit of probiotics considering that optimizing enteral nutrition is a priority in extremely preterm neonates, including those with intrauterine growth restriction, who are at a higher risk for feed intolerance and NEC. The increasing number of reports on routine use of probiotics indicates that difficulty in accessing clinically proven and safe probiotic products is not a significant barrier towards a change in practice. Strategies to address important gaps in knowledge and the impact of routine use of probiotic supplementation are reviewed to prepare for what lies ahead in this field.
机译:随机对照试验的系统评论表明,益生菌补充显着降低了预发性低初始新生儿的不良反应的风险性疾病性结合炎(NEC)。考虑到这一人口中NEC的健康负担,有利于益生菌补充的实践变化是合理的。即使疾病的基线发病率低至5%,NEC风险的降低似乎也发生。促进饲料耐受性是益生菌的显着优势,考虑到优化肠内营养是极其早产的优先事项,包括患有宫内生长限制的人,他们处于饲料不耐受和NEC的风险较高。越来越多的常规使用益生菌的报告表明,在临床上证明和安全的益生菌产品中难以实现实践变化的重要障碍。解决知识中重要差距的策略以及常规使用益生菌补充的影响,以便为该领域的前方做好准备。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号